Longitudinal live animal micro-CT allows for quantitative analysis of tumor-induced bone destruction

Bone

Volumn 48, Issue 1, 2011, Pages 141-151

  Johnson, Lindsay C ^a,b   Johnson, Rachelle W ^b,c   Munoz, Steve A ^b,d   Mundy, Gregory R ^b,c,d   Peterson, Todd E ^b,d   Sterling, Julie A ^b,c  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone destruction; Faxitron; Imaging; Micro CT; Osteolysis; Radiography

Indexed keywords

ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; LONGITUDINAL STUDY; MICRO-COMPUTED TOMOGRAPHY; MONITORING; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; TIBIA; TUMOR CELL;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; REPRODUCIBILITY OF RESULTS; TIBIA; TOMOGRAPHY, X-RAY COMPUTED; X-RAY MICROTOMOGRAPHY;

EID: 78650304408     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.05.033     Document Type: Article

References (17)

1. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27(3):165-176.
2. Yoneda T., Michigami T., Yi B., Williams P.J., Niewolna M., Hiraga T. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treat Rev 1999, 25(5):293-299.
3. Yin J.J., Selander K., Chirgwin J.M., Dallas M., Grubbs B.G., Wieser R., et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999, 103:197-206.
4. Gallwitz W.E., Guise T.A., Mundy G.R. Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest 2002, 110:1559-1572.
5. Fisher J.L., Schmitt J.F., Howard M.L., Mackie P.S., Choong P.F., Risbridger G.P. An in vivo model of prostate carcinoma growth and invasion in bone. Cell Tissue Res 2002, 307(3):337-345.
6. Rosol T.J., Tannehill-Gregg S.H., LeRoy B.E., Mandl S., Contag C.H. Animal models of bone metastasis. Cancer 2003, 97(Suppl 3):748-757.
7. Rajarubendra N., Bolton D., Lawrentschuk N. Diagnosis of bone metastases in urological malignancies-an update. Urology Mar 24 2010, Electronic publication ahead of print.
8. Bussard K.M., Mastro A.M. Ex-vivo analysis of the bone microenvironment in bone metastatic breast cancer. J Mammary Gland Biol Neoplasia 2009, 14(4):387-395.
9. Cowey S., Szafran A.A., Kappes J., Zinn K.R., Siegal G.P., Desmond R.A., et al. Breast cancer metastasis to bone: evaluation of bioluminescent imaging and microSPECT/CT for detecting bone metastasis in immunodeficient mice. Clin Exp Metastasis 2007, 24:389-401.
10. Missbach-Guentner J., Dullin C., Zientkowska M., Domeyer-Missbach M., Kimmina S., Obenauery S., et al. Flat-panel detector-based volume computed tomography: a novel 3D imaging technique to monitor osteolytic bone lesions in a mouse tumor metastasis model. Neoplasia 2007, 9(9):755-765.
11. Costa L., Major P.P. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 2009, 6(3):163-174.
12. Virk M.S., Petrigliano F.A., Liu N.Q., Chatziioannou A.F., Stout D., Kang C.O., et al. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone. Bone Jan 2009, 44(1):160-167.
13. Ben-Haim S., Israel O. Breast cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med Nov 2009, 39(6):408-415.
14. Polascik T.J. Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Dev Ther 2009, 3:27-40.
15. Labrinidis A., Hay S., Liapis V., Ponomarev V., Findlay D.M., Evdokiou A. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res 2009, 15(10):3451-3461.
16. Guise T.A., Mundy G.R. Cancer and bone. Endocr Rev 1998, 19(1):18-54.
17. McNeil B.J. Rationale for the use of bone scans in selected metastatic and primary bone tumors. Semin Nucl Med 1978, 8(4):336-345.